Fig. 1.
FOXD3-AS1 promoted chemo-resistance in NSCLC cells. a qRT-PCR determination of FOXD3-AS1 in cell lines including NHBE, A549, H1299, A549/DDP and H1299/DDP. b qRT-PCR determination of FOXD3-AS1 in A549 and H1299 cells with pcDNA3.1 or pcDNA3.1-FOXD3-AS1 transfection. c–e CCK-8 assay determination of IC50 values (cisplatin) in A549 and H1299 cells with pcDNA3.1 or pcDNA3.1-FOXD3-AS1 transfection. f qRT-PCR determination of FOXD3-AS1 in A549 and H1299 cells with si-NC or si-FOXD3-AS1 transfection. g–i CCK-8 assay determination of IC50 values (cisplatin) in A549 and H1299 cells with si-NC or si-FOXD3-AS1 transfection. N = 3 biological samples, and each sample was assayed in triplicates. Significant different between different treatment groups were shown as *P < 0.05 and **P < 0.01